6
Views
0
CrossRef citations to date
0
Altmetric
Research

Patent Evaluation Oncologic, Endocrine & Metabolic: Novel tyrosine kinase inhibitors

Pages 211-212 | Published online: 29 Feb 2008
 

Abstract

Two heterocyclic series of compounds, both bicyclic and tricyclic, are disclosed in two patent applications as novel EGFR inhibitors with claims including utilities in treating human diseases such as cancer, diabetes and pancreatitis.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.